Novogen Retained Earnings (Accumulated Deficit) 2010-2023 | KZIA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Novogen retained earnings (accumulated deficit) from 2010 to 2023. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Novogen Retained Earnings (Accumulated Deficit) 2010-2023 | KZIA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Novogen retained earnings (accumulated deficit) from 2010 to 2023. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$173B
Vertex Pharmaceuticals (VRTX)	$127.1B
Gilead Sciences (GILD)	$114.2B
Bristol Myers Squibb (BMY)	$112.1B
CSL (CSLLY)	$91B
Regeneron Pharmaceuticals (REGN)	$89.7B
GSK (GSK)	$74.4B
Argenex SE (ARGX)	$35.2B
Alnylam Pharmaceuticals (ALNY)	$35.2B
Biogen (BIIB)	$25.4B
BioNTech SE (BNTX)	$25.4B
Illumina (ILMN)	$24.2B
Moderna (MRNA)	$19.9B
BeiGene (BGNE)	$19.7B
Incyte (INCY)	$15.6B
Genmab (GMAB)	$14.8B
Insmed (INSM)	$13B
Vaxcyte (PCVX)	$13B
BioMarin Pharmaceutical (BMRN)	$12.6B
Sarepta Therapeutics (SRPT)	$12.2B
Bio-Techne Corp (TECH)	$12B
Exelixis (EXEL)	$10.1B
Exact Sciences (EXAS)	$10.1B
QIAGEN (QGEN)	$10B
Revolution Medicines (RVMD)	$9.9B
Intra-Cellular Therapies (ITCI)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.4B
Roivant Sciences (ROIV)	$8.7B
Repligen (RGEN)	$8.2B
Ascendis Pharma (ASND)	$7.8B